Head-to-head · WeighScore
Medsol RX vs Omada Health
The verdict
Medsol RX takes it — 61/100 to 55.6/100.
Medsol RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Medsol RX is a GLP-1 weight-loss telehealth program offering compounded semaglutide (from $209/mo) and tirzepatide, prescribed by board-certified clinicians via OpenLoop and shipped nationwide.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Medsol RX | Omada Health |
|---|---|---|
| WeighScore | 61/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #306 | #435 |
| Semaglutide | $209/mo (compounded) | Not disclosed |
| Tirzepatide | $250/mo (compounded) | Not disclosed |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #306 · C
Strengths
- Compounded semaglutide from $209/mo (12-mo plan) and tirzepatide from ~$250/mo; HSA/FSA eligible with Klarna financing
- Every plan bundles the medication, a dedicated care coach, custom treatment plan, medical oversight, and free shipping
- Board-certified clinicians via OpenLoop; same-day approvals; ships nationwide
- Month-to-month option ($199 first month) with no long-term commitment, plus microdosing and wellness add-ons
Where it loses points
- Doesn't name its compounding pharmacy (generic 'certified U.S. pharmacies')
- No legal entity name published on the site
- Tirzepatide pricing is given as a range ($250-$1,400/mo), not a fixed rate
- Compounded GLP-1s are not FDA-approved (the site discloses this)
Graded #435 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.